OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Additional global safety updates across all TAVO™ clinical studies
SAN DIEGO and PENNINGTON, N.J., Nov. 5, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced it will present a poster highlighting a safety and biomarker analysis on its lead product candidate, TAVO™, at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.
The poster, titled "Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis," will be presented by author Alain Algazi, MD on Saturday, November 9th from 12:35 p.m. – 2:05 p.m. and from 7:00 p.m. – 8:30 p.m. Eastern Time.
The SITC abstract titles are listed on the conference website under Abstracts at https://sitc.sitcancer.org/2019/abstracts/titles.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec has built a deep and diverse clinical pipeline utilizing its primary technology, TAVO™ (tavokinogene telseplasmid) as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non- responders. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO™ is a registered trademark of OncoSec Medical Incorporated.
Forward Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the status, progress and results of our clinical programs; our ability to obtain regulatory approvals for, and the level of market opportunity for our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; expectations regarding our liquidity and performance, including expense levels, sources of capital and ability to maintain operations as a going concern; the competitive landscape of our industry; and general market, economic and political conditions; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Head of Corporate Communications
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-tavo-immune-biomarker-data-associated-with-positive-clinical-response-from-ongoing-keynote-studies-at-the-society-for-immunotherapy-of-cancer-sitc-34th-annual-meeting-300951421.html
SOURCE OncoSec Medical Incorporated
Released November 5, 2019